Rabies virus inactivated antigen, A
Star1
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Rabavert
- Generic Name
- Rabies virus inactivated antigen, A
- DrugBank Accession Number
- DB10283
- Background
Rabies virus inactivated antigen, A is an inactivated virus vacine for the intramuscular injection. It is an active immunization against rabies that can be administered pre- or post-exposure to the rabies virus.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Inactivated - Synonyms
- Rabies virus strain flury lep antigen (propiolactone inactivated)
- Rabies virus vaccine flury-lep strain
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alemtuzumab. Altretamine The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Altretamine. Amsacrine The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Amsacrine. Anakinra The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Anakinra. Anifrolumab The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Anifrolumab. Antilymphocyte immunoglobulin (horse) The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Antilymphocyte immunoglobulin (horse). Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image RabAvert Kit; Powder, for suspension 2.5 [iU]/1mL Intramuscular Bavarian Nordic A/S 1997-11-11 Not applicable US RabAvert Kit 2.5 [iU]/1mL Intramuscular A-S Medication Solutions 2014-07-08 2020-03-31 US RabAvert Kit 2.5 [iU]/1mL Intramuscular A-S Medication Solutions 2016-12-19 Not applicable US RabAvert Kit 2.5 [iU]/1mL Intramuscular GSK Vaccines GmbH 2014-07-08 2020-03-31 US RabAvert Kit 2.5 [iU]/1mL Intramuscular GlaxoSmithKline Biologicals SA 2016-12-19 2024-01-31 US
Categories
- ATC Codes
- J06AA06 — Rabies serum
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- FK894Q51YE
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Basic Science Rabies 2 4 Completed Basic Science Rabies Human 1 4 Completed Prevention Rabies 1 4 Completed Prevention Rabies Vaccine Allergy 1 4 Completed Treatment Rabies 1 4 Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) / Rabies 1 4 Unknown Status Health Services Research Rabies 1 4 Withdrawn Prevention Viral Disease 1 3 Active Not Recruiting Prevention Antibody Titer / Rabies Human 1 3 Active Not Recruiting Prevention Malaria 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intradermal; Intramuscular 2.5 IU/0.5mL Kit Intramuscular 2.5 [iU]/1mL Kit; powder, for suspension Intramuscular 2.5 [iU]/1mL Injection, powder, lyophilized, for solution Intramuscular ≥ 2.5 IU Injection, powder, lyophilized, for solution Intramuscular 2.5 IU/ml Injection, powder, for solution Intramuscular 2.5 iu/mL Injection, powder, for solution Intramuscular 2.5 IU - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at November 30, 2015 21:24 / Updated at June 12, 2020 16:52